Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis: a systematic review.

Miriam Martos-Fernández, Manel Saez-Barba, Jose López-López, Albert Estrugo-Devesa, Jose María Balibrea-Del-Castillo, Coro Bescós-Atín

Journal: Oral surgery, oral medicine, oral pathology and oral radiology 2018;125(5):431-439

PMID: 29550081

Abstract

OBJECTIVE

The purpose of this study was to evaluate the healing benefit provided by the antioxidant and antifibrotic properties of pentoxifylline-tocopherol or pentoxifylline-tocopherol-clodronate in combination therapy for osteoradionecrosis.

STUDY DESIGN

We searched for relevant reports in PubMed by using a combination of "osteoradionecrosis" and the following keywords: "pentoxifillyne," "tocopherol," "vitamin E," or "clodronate." We considered articles in English or Spanish, with no limitations on the publication date.

RESULTS

The combination of pentoxifylline plus tocopherol with or without clodronate was found to be effective for the treatment of mandibular osteoradionecrosis, although data were generally scarce and mostly came from retrospective case series.

CONCLUSIONS

This drug therapy is well tolerated and could be promising for the treatment of mandibular osteoradionecrosis, but prospective randomized controlled clinical trials are needed for further clarification.

Copyright © 2018 Elsevier Inc. All rights reserved.

Address: Oral and Maxillofacial Surgery Department, Parc Taulí Hospital, Barcelona, Spain. Electronic address: [email protected].; Oral and Maxillofacial Surgery Department, Vall d'Hebron Hospital, Barcelona, Spain.; Odontostomatology Department, Dental School, University of Barcelona, Barcelona, Spain.; General and Digestive Surgery Department, Vall d'Hebron Hospital, Barcelona, Spain.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.